The debate over appropriate treatment for dual carcinoma in situ, or DCIS, is part of an even bigger debate about what many specialists call the “overdiagnosis” of cancer, especially cancers of the breast, prostate and thyroid. Kevin Hughes, HMS associate professor of surgery at Massachusetts General Hospital, is quoted.
